Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome Hematologic Malignancy

Purpose Primary plasma cell leukemia (pPCL) is a rare and aggressive malignancy with a poor prognosis. With conventional chemotherapy, patients typically die within 1 year. In all but one of the retrospective studies reported to date, bortezomib and lenalidomide seem to improve survival. We conducted a prospective phase II trial in patients with pPCL to assess the efficacy of an alternate regimen that combines standard chemotherapy, a proteasome inhibitor, and high-dose melphalan and autologous stem cell transplantation (HDM/ASCT) followed by either allogeneic transplantation or bortezomib/lenalidomide maintenance. Patients and Methods Patients 70 years old and younger with newly diagnosed pPCL received four alternating cycles of bortezomib, dexamethasone plus doxorubicin or cyclophosphamide. Peripheral blood stem cells were collected from responding patients with
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Myeloma, Diagnosis & Staging, Chemotherapy Hematologic Malignancy Source Type: research

Related Links:

Publication date: Available online 15 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Alan Burnett, Richard StoneAbstractDespite the approval of 8 new drugs for AML since 2017, the disease remains challenging given the significant toxicity associated with available treatments and relatively low cure rates, especially in older adults. While advantageous for patients, self-congratulatory rejoicing about the new agents would be extremely premature. Questions abound about the need for a specific vs less specific FLT3 inhibitor (e.g midostautin) in the upfront setting and whether a single agent (gilteritni...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Despite the approval of 8 new drugs for AML since 2017, the disease remains challenging given the significant toxicity associated with available treatments and relatively low cure rates, especially in older adults. While advantageous for patients, self-congratulatory rejoicing about the new agents would be extremely premature. Questions abound about the need for a specific vs less specific FLT3 inhibitor (e.g midostautin) in the upfront setting and whether a single agent (gilteritnib), albeit better than chemotherapy is sufficient for relapsed disease.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Leukemia, Published online: 14 February 2020; doi:10.1038/s41375-020-0742-zMultiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease
Source: Leukemia - Category: Hematology Authors: Source Type: research
Leukemia, Published online: 14 February 2020; doi:10.1038/s41375-020-0745-9A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
Source: Leukemia - Category: Hematology Authors: Source Type: research
to “Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study” [Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e425-429]
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Tags: Corrigendum Source Type: research
Publication date: Available online 12 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): O.V. Lazareva, A.G. Turkina, E.Yu Chelysheva, A.A. Kulikovsky, M.A. Galayko, O.M. Senderova, V.M. Pepeliaeva, S.V. Meresiy, A.S. Luchinin, G.I. Milutina, L.V. Gavrilova, L.B. Avdeeva, E.B. Dasheeva, O.Yu Vinogradova, H.L. Julhakyan, S.M. KulikovIntroductionRussia took part in the multicenter population-based Study (Europe) and included 6.8% adult patients (pts) with newly diagnosed chronic myeloid leukemia (CML) (Hoffman V et al. 2016).ObjectiveTo analyze the mortality in the Russian cohort of patients (pts) with new...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOur results demonstrate that Egyptian children diagnosed with JMML have high frequency of NRAS/KRAS mutations and lower frequency of PTPN11 mutations as compared to previous studies. The concept of mutually exclusive RAS pathway mutations was clearly observed in our patients. All cancer centers in our region should start implementing molecular diagnostics methods before confirming the diagnosis of JMML and before offering HSCT.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study aimed to demonstrate the impact of LSCs on MRD induction day (14) and Day (28) on overall survival (OS) and disease free survival (DFS) as well as compare it to MRD status. 84 De novo adult AML patients tested for LSCs panels CD38/CD123/CD34/CD45, CD90/CD133/CD45/CD33 as well as different regular MRD panels. Day 14post induction, high expression of CD123% and CD133% had an adverse impact on both OS and DFS (p=0.004 &P=
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Russia took part in the multicenter population-based Study (Europe) and included 6.8% adult patients (pts) with newly diagnosed chronic myeloid leukemia (CML) (Hoffman V et al. 2016).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Current Trial Report Source Type: research
More News: Bone Graft | Cancer & Oncology | Chemotherapy | Dexamethasone | Hematology | Leukemia | Myeloma | Revlimid | Stem Cell Therapy | Stem Cells | Study | Transplants | Velcade